Navigation Links
Tianyin Pharmaceutical Co., Inc. Announces First Quarter 2009 Financial Results
Date:11/11/2008

ock began trading on the NYSE Alternext U.S. (formerly known as the American Stock Exchange) under the ticker "TPI" at market open on Wednesday, October 1, 2008. In addition, the Company's board of directors approved a $3 million stock repurchase program on October 28, 2008.

"In the first quarter of fiscal year 2009, our organic growth from existing core products and new products launched in fiscal year 2008 demonstrates the success of our growth strategy. We received two approvals from the Chinese SFDA to produce Laonian Kechuan Tablets and Fuke Zhidai Tablets. We plan to launch these two drugs before the end of 2008 and we are optimistic that these new drugs will further improve our profitability and be additional growth contributors to our top-line and bottom-line numbers. We will continue to focus on broadening our product portfolio, increasing our sales and marketing activities, and further expanding our distribution network. Our extensive market research provides evidence that we are well positioned in the Chinese pharmaceutical industry, the benefit of which will continue to support our revenue and net income growth throughout fiscal 2009 and beyond," concluded Dr. Jiang.

Conference Call

The Company will host a conference call to discuss the 2009 first quarter financial results on Tuesday, November 11, 2008 at 8:30 a.m. EST. Interested participants should call 800-762-8795 within the United States, or US +1-480- 629-9031 if calling internationally. The conference ID is 3940851. It is advisable to dial in approximately 5-10 minutes prior to 8:30 a.m. EST. If you are unable to participate in the call at the scheduled time, a playback will be available on Tuesday, November 11, 2008 at 11:30 a.m. ET through Thursday, November 27, 2008 at 11:59 p.m. ET. To listen to the playback, please call 800-406-7325 from within the United States, or US +1 303-590-3030 internationally. Please use pass code 3940851 for the replay.

About Tianyin Pharm
'/>"/>

SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Tianyin Pharmaceutical Co., Inc. to Present at Rodman & Renshaw Annual Global Investment Conference in New York City on November 11, 2008 at 12:00 p.m. EST
2. Tianyin Pharmaceutical to Present at the Brean Murray All-Cap All-China Conference in New York City on May 20, 2008 at 10:15 a.m. EDT
3. Tianyin Pharmaceutical Announces SFDA Approval to Market Azithromycin Dispersible Tablets
4. Tianyin Pharmaceutical Appoints Three New Independent Board Members
5. Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results
6. Tianyin Pharmaceutical, Inc. to Host 2008 Second Quarter Earnings Conference Call on Thursday, February 14, 2008 at 4:15 p.m. EST
7. Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights
8. Stem Cell Sciences Licenses Stem Cell Technology to Leading Provider of Genetically Modified Models for Pharmaceutical Research
9. Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction
10. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
11. Shengtai Pharmaceutical Schedules 2009 First Quarter Financial Results and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Sept. 2, 2015 Research and ... addition of Jain PharmaBiotech,s new report ... their offering. An increasing ... biotechnology industries is anticipated. Nanotechnology will be ... - from formulations for optimal delivery to ...
(Date:9/2/2015)... Research and Markets ... Jain PharmaBiotech,s new report "Biomarkers - Technologies, ... This report follows the broad definition of ... objectively measured and evaluated as an indicator of ... pharmacological responses to a therapeutic intervention. Tests based ...
(Date:9/2/2015)... 2015  Neurotech Pharmaceuticals, Inc., announced today the ... Phase 2 clinical trial of NT-503 Encapsulated Cell ... subfoveal choroidal neovascularization secondary to age related macular ... endothelial growth factor (VEGF) receptor protein continuously produced ... landmark proof-of-concept study will evaluate NT-503 ECT as ...
(Date:9/2/2015)... Israel , September 2, 2015 ... the intent of the National Institute of Allergy and Infectious ... (NIH) within the Department of Health and Human Services (HHS), ... in the United States in the ... universal flu vaccine candidate, Multimeric-001 (M-001), as a primer vaccine, ...
Breaking Biology Technology:Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 3Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3
... Biological Sciences Research Council (BBSRC) have taken a step ... disease of livestock - after successfully assembling the virus ... 2011) in the journal Proceedings of the National ... tools to develop vaccines with useful new properties. ...
... German . , In light of the increasing demand ... for manufacturers to understand just how these particles influence bodily ... which there has been a dearth of knowledge. Studies on ... a negative effect on the cardiovascular system. Yet, it remained ...
... , the leading life sciences employment and news website, ... the campaign,s eighth edition. (Logo: http://photos.prnewswire.com/prnh/20040907/CLTU006LOGO ... across Kansas, Illinois, Indiana, Iowa, Michigan, Minnesota, Missouri, Nebraska, ... an electronic and printed campaign map that ...
Cached Biology Technology:Scientists take a step towards developing better vaccines for bluetongue 2Scientists take a step towards developing better vaccines for bluetongue 3Artificial nanoparticles influence the heart rate 2Artificial nanoparticles influence the heart rate 3BioSpace Spotlights the Growing Midwest Life Science Community 2
(Date:9/2/2015)... September 2, 2015 ... implied in a system which uses identical human ... iris, vein, DNA and finger print. Increasing number ... develop such system which provides high level of ... Patterns and tokens are vulnerable to attacks. Furthermore, ...
(Date:8/26/2015)... India , August 26, 2015 ... Three, Four, and Five Factor), Application (Travel & Immigration, ... Geography - Global Forecast to 2020", published by MarketsandMarkets, ... Billion by 2020, growing at a CAGR of 17.7% ... Tables and 82 F igures spread through 169 ...
(Date:8/20/2015)... CLARA, Calif. , Aug. 20, 2015 /PRNewswire/ ... company focused on improving the user experience and ... and vision technologies, today announced that its ... voice biometric authentication software to be FIDO ... tested TrulySecure for compliance with the FIDO UAF ...
Breaking Biology News(10 mins):Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 2Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 3Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5
... of Medicine have made major discoveries that could lead to ... mouse study, the team located key molecules that switch on ... when parts of these pathways were blocked with a pain ... findings are published online ahead of print in the March ...
... chemistry experiment, in which beautiful plant-like structures sprout in a ... that aim to shed light on the origins of life ... could have kick-started life are the topic of a story ... . C&EN is the weekly newsmagazine of the American Chemical ...
... 20, 2013 - Elsevier, a world-leading provider of scientific, ... to announce the launch of Wound Medicine ... Research and Applications . Published in print ... is devoted to the clinical, scientific and health ...
Cached Biology News:Researchers spot molecular control switch for preterm lung disorders 2Elsevier announces the launch of a new journal: Wound Medicine 2
...
... 5-OxoETE-d7 is used as an internal standard ... isotope dilution mass spectrometry. 5-OxoETE is a ... of 5-HETE in human neutrophils. It stimulates ... EC50 of 2 nM. 5-OxoETE selectively stimulates ...
Mouse monoclonal antibody raised against a full length recombinant ATF3. NCBI Entrez Gene ID = ATF3...
... The pAcAB4 vector is a 10.0 kb ... contains two,copies of the AcNPV polyhedrin promoter ... the first p10,promoter is a Sma I ... sequences. Upstream of this,an inverted polyhedrin promoter ...
Biology Products: